VBI Vaccines, Inc. (VBIV) Major Shareholder Purchases $9,455,000.00 in Stock

VBI Vaccines, Inc. (NASDAQ:VBIV) major shareholder Life Sciences Maste Perceptive bought 3,100,000 shares of the firm’s stock in a transaction on Thursday, October 26th. The shares were purchased at an average price of $3.05 per share, for a total transaction of $9,455,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

TRADEMARK VIOLATION NOTICE: “VBI Vaccines, Inc. (VBIV) Major Shareholder Purchases $9,455,000.00 in Stock” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.com-unik.info/2017/11/02/vbi-vaccines-inc-vbiv-major-shareholder-purchases-9455000-00-in-stock.html.

A number of research firms have commented on VBIV. Canaccord Genuity began coverage on VBI Vaccines in a research report on Wednesday. They set a “buy” rating and a $10.00 target price on the stock. Zacks Investment Research downgraded VBI Vaccines from a “buy” rating to a “hold” rating in a research report on Saturday, July 15th. ValuEngine upgraded VBI Vaccines from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, Noble Financial reiterated a “buy” rating on shares of VBI Vaccines in a research report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $10.00.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. California State Teachers Retirement System bought a new position in VBI Vaccines during the 2nd quarter valued at $167,000. State Street Corp bought a new position in VBI Vaccines during the 2nd quarter valued at $831,000. Northern Trust Corp bought a new position in VBI Vaccines during the 2nd quarter valued at $883,000. TIAA CREF Investment Management LLC bought a new position in VBI Vaccines during the 2nd quarter valued at $262,000. Finally, Teachers Advisors LLC bought a new position in VBI Vaccines during the 2nd quarter valued at $195,000. 31.50% of the stock is owned by hedge funds and other institutional investors.

VBI Vaccines Company Profile

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

What are top analysts saying about VBI Vaccines Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for VBI Vaccines Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit